Shingles vaccine safety in pregnancy under review for immunocompromised women
NCT ID NCT05811754
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide real-world safety data for this group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HZ/su vaccine (Shingrix)
- What this could lead to
- If successful, this study could provide reassurance that the HZ/su vaccine is safe to use during pregnancy in immunocompromised women.
- What could go wrong
- This is an observational study, not a controlled trial, so it can only show associations, not cause and effect. Results may be limited by the number of pregnancies studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,844 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult pregnant women, 18-49 years of age, diagnosed with an immunocompromised condition who were members of any of the 4 participating Sentinel Research Partners.
- Ages
-
18 to 49 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant who is pregnant with a pregnancy start date between 01 July 2021 and 30 June 2026. Live births are to be followed for 1 year. * Participant is a female aged 18-49 years on the pregnancy start date. * Participant meets study definition of systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis (PsO)/psoriatic arthritis (PsA), solid organ transplant (SOT), stem cell transplant (SCT), hematologic malignancies (HM), solid tumors (ST), or human immunodeficiency virus (HIV). Codes for immunocompromised conditions will be identified in the health plan claims of the Distributed Research Network (DRN) during the period 273 days prior to the pregnancy start date through the first trimester (98 days after the pregnancy start date). Diagnoses recorded through the first trimester will be included to account for women who may not have frequent visits prior to pregnancy and may have a more complete assessment of medical conditions during the first prenatal care visit. * Participant has at least 273 days of continuous health plan enrollment with medical and drug benefits prior to the start of pregnancy through the delivery date, with gaps of up to 45 days in coverage being permitted. The 273-day pre-pregnancy period through the first trimester (a period of 98 days after the pregnancy start date) was chosen to allow identification of potential confounders of interest. In Sentinel projects, gaps of 45 days or less in health plan enrolment are typically considered administrative gaps (and not lapses in health plan coverage) and ignored. Exclusion Criteria: * Participant was exposed to a medication(s) that presents a known increased risk for fetal malformations. * Participant delivered an infant identified as having a chromosomal or genetic anomaly. * Ectopic pregnancies, molar pregnancies or induced abortions. * Multigestation (e.g., twin) pregnancies.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematologic malignancies are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Canton, Massachusetts, 02021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pilot study to evaluate the effect of nicotinamide riboside on immune activation in psoriasis
- Simulator-Based assessment of driving performance in patients with Parkinson's disease and multiple sclerosis
- Ocular surface changes and meibomian gland dysfunction in rheumatologic patients: a Cross-Sectional analytical study
- Contrasting chronic inflammation and neurodegeneration using the human amniotic mesenchymal cell secretome as an innovative therapeutic strategy
- VIGIP-SEP2: evaluation of the impact of the training of patients by nurses on the adverse drug reaction reporting by RRMS patient via a mobile application: a randomized real-life study
- Can a blood test catch lupus flares earlier?